Drug Profile
Agomelatine - Servier
Alternative Names: AGO-178; AGO178C; Alodil; Melitor; S-20098; S-20098-F55; Thymanax; Valdoxan; VestinLatest Information Update: 01 Mar 2022
Price :
$50
*
At a glance
- Originator Servier
- Developer Novartis; Servier
- Class Acetamides; Antidepressants; Anxiolytics; Behavioural disorder therapies; Hypnosedatives; Sleep disorder therapies; Small molecules
- Mechanism of Action Melatonin MT1 receptor agonists; Melatonin MT2 receptor agonists; Serotonin 2C receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Major depressive disorder
- Suspended Generalised anxiety disorder
- No development reported Obsessive-compulsive disorders
- Discontinued Sleep disorders
Most Recent Events
- 11 Aug 2017 Suspended - Phase-II for Generalised anxiety disorder (In adolescents, In children) in Poland, Romania, Estonia, Hungary, Sweden, Finland (PO,Tablet) (Servier email communication, August 2017)
- 11 Aug 2017 Suspended - Phase-II for Generalised anxiety disorder in South Africa (PO, capsule) (Servier email communication, August 2017)
- 11 Aug 2017 Suspended - Phase-III for Generalised anxiety disorder in Canada, Poland, Russia, Czech Republic, Australia, Germany, Hungary, Slovakia, France, Ukraine, Finland, Argentina (PO,Capsule) (Servier email communication, August 2017)